Product Compliance And Certification For Medical Device In Australia

Scope and evidence must be confirmed before any paid tests or filings.

A medical device in Australia is not cleared by a single generic ‘certification’. Start with its actual intended purpose, mechanism, users, design and supply model. Depending on those facts, the product may need TGA medical-device conformity evidence and inclusion in the Australian Register of Therapeutic Goods (ARTG), and separate radio, radiation or other controls. This route map concerns the whole category of medical devices—not a dedicated wearable-device assessment.

Decide whether the product is a medical device

Under section 41BD of the Therapeutic Goods Act 1989, intended medical purpose and principal mode of action matter. Describing something as a ‘health product’ or receiving an overseas certificate does not decide its Australian status. Compare the intended-use statement, instructions, website claims and technical operation before applying a class:

Diagnosis, treatment, clinical monitoring or prevention claimed for humans: assess the medical-device definition.
Testing a human specimen for clinical information: assess the separate IVD definition and Schedule 2A.
Main therapeutic action through pharmacological, immunological or metabolic means: investigate medicine/biological/boundary-product rules; do not assume a device.
Wellness-only information versus clinical decision support or automated diagnosis: document exactly what software outputs and who makes the clinical decision.
Sterile, measuring, implantable, invasive, powered, wireless or radiation-emitting characteristics: retain them as classification and parallel-regime triggers, not a class assignment by themselves.

Australian device regulatory stack: TGA, ACMA and radiation

Trigger / example	Regulatory layer and proof	Next question before commitment
A physical therapeutic device (e.g., dressing, syringe, implant)	TGA: Essential Principles, Schedule 2 risk class, appropriate conformity assessment and normally ARTG inclusion.	Where and for how long used; sterile/measurement/implant status; applicable classification rules?
Human-specimen testing or diagnostic analyser	TGA: IVD pathway, Schedule 2A Classes 1–4 and performance evidence.	What specimen, who is tested, clinical purpose and harm from false results?
Standalone clinical software or AI decision output	TGA: assess SaMD/device definition, exclusions or exemptions, software classification and validation/cybersecurity evidence.	Is the output merely data handling or a diagnosis, screening or treatment recommendation?
Drug-containing or substance-based combination	TGA: boundary/combination analysis; medicine, biological or medical-device route depends on principal action and specific rules.	Does the main effect arise physically or pharmacologically, immunologically or metabolically?
Bluetooth/Wi-Fi/radio, powered electronics	ACMA radio, EMC, EME and possibly telecommunications rules may apply independently of TGA; confirm the applicable supplier, evidence and RCM labelling duties. Assess EESS electrical safety separately: its medical-equipment guidance distinguishes devices used by professionals or under professional instruction (outside EESS) from some mains-powered equipment purchased and used independently at home (potentially in scope even if listed with TGA). Check voltage, intended users, supply context and the power adapter/charger independently; medical-device status alone is not an EESS exemption.	Which transmitters, bands, power supply, supplier and technical standards are in scope?
X-ray or other regulated ionising radiation equipment	TGA device route plus potentially state/territory radiation licensing, registration or user controls.	Which radiation source and installation/use jurisdiction; whose licence is required?
Australian supply, labels, UDI and public promotion	TGA sponsor/ARTG, Essential Principle 13, UDI rollout and advertising restrictions; ongoing vigilance.	Who is sponsor; what ARTG kind and risk class; UDI start date; what claims are advertised?

Classification forks that change the route

Non-IVD classes commonly run from Class I to III, with additional distinctions for sterile or measuring devices; IVDs use Classes 1–4. Do not transfer a foreign risk class mechanically. Apply every relevant Australian rule to the documented intended purpose; if multiple rules apply, use the highest applicable classification. In particular:

An invasive or implantable product requires duration, body site and contact evidence; a picture or trade name is insufficient.
An IVD requires its own specimen, user, testing setting and false-result risk assessment; an ordinary non-IVD rule cannot replace Schedule 2A.
Software that independently processes clinical information may be a medical device even without hardware; check specific Australian exclusions and exemptions rather than assuming wellness status.
A medical device containing an ancillary medicine or a combination product needs a documented primary-mode-of-action analysis; TGA boundary guidance changed for specified products from 1 January 2026.
Check saline-only flushing products under the September 2026 amendment: a non-invasive device containing only saline, intended to maintain the patency of or flush the lumen of another device (for example, a pre-filled saline flush syringe), is Class IIa under Schedule 2, clause 2.2A for ARTG applications made on or after 8 September 2026. Regulation 11.88 provides a five-year transition for kinds covered by applications made before commencement; verify the application date and exact formulation.

Upcoming software exemption change (1 November 2026): The 2026 amendment revises Schedule 4 item 2.15 for specified clinical decision-support software. Before relying on this exemption for supply on or after that date, check whether the product only recommends to a health professional, does not process device images/signals or replace professional judgement or itself decide diagnosis/treatment, and makes its reasoning verifiable. The amendment’s regulation 11.90 also addresses software manufactured before commencement but intended for use afterward; do not assume grandfathering.

Manufacturer–sponsor evidence handoff

Before seeking quotations for testing or Australian inclusion, obtain a version-controlled dossier. An evidence gap cannot be resolved by purchasing an unrelated ISO certificate; voluntary standards are methods of demonstrating conformity, not automatic legal market authorisations.

Evidence / decision record	Manufacturer prepares or controls	Australian sponsor verifies / must access
Intended purpose and claim inventory	Models, indications, users, mechanism, IFU, website and software outputs.	Match Australian marketed claims and proposed ARTG scope.
Classification rationale	Australian rule-by-rule justification: non-IVD Schedule 2 or IVD Schedule 2A; exceptions.	Review class, product grouping, GMDN and sponsor/manufacturer combination.
Essential Principles evidence index	Risk management, design verification, test results, clinical/performance evaluation and applicable deviations.	Obtain or be able to retrieve current objective evidence for TGA requests.
Manufacturing / conformity evidence	Appropriate declaration or conformity/QMS evidence; overseas approvals with matching device, indications and design.	Check evidence acceptability, any Manufacturer Evidence acceptance, application attachments and audit risk.
Australian supply/label pack	English instructions and label artwork, intended use, warnings, identifiers, software version as relevant.	Sponsor name/address delivery method, UDI timetable, advertising and record access.
After-market and interface files	Complaints, field actions, changes, cyber updates, batch traceability and distribution inputs.	Written escalation responsibilities, reporting, recall and parallel ACMA/radiation obligations.

Five Australian medical-device launch gates: evidence, sponsor and ARTG

Use these gates as a sequence, not as an assumed approval timeline:

Freeze the Australian intended purpose and compare physical, software and specimen-based functions; resolve device/IVD/borderline/excluded or exempt status.
Manufacturer documents the Australian classification rules and checks whether product grouping, variants or accessories need distinct ARTG treatment.
Select acceptable Australian or comparable-overseas conformity evidence for the exact device and check whether a Manufacturer Evidence application is required and accepted; limited low-risk categories follow different submission rules.
Identify a qualifying Australian-based sponsor, secure a manufacturer information-sharing arrangement and prepare the ARTG inclusion application with GMDN, device kind and supporting documents.
Do not start ordinary Australian supply until the required ARTG inclusion is in place, or a verified lawful exclusion/exemption/authorisation applies; separately close applicable ACMA and radiation gates.

ARTG entries are specific to a sponsor, manufacturer and kind of device. Another importer’s ARTG entry generally does not authorise a new sponsor to supply under that entry. Equally, an EU CE certificate or FDA clearance may support evidence assessment but never substitutes automatically for an Australian ARTG inclusion.

Australian labels, UDI and promotional claims

Treat packaging, device information and advertising as a release workstream—not a cosmetic translation exercise. Australian Essential Principle 13 governs information supplied with a medical device, and regulation 10.2 governs sponsor identification.

Provide required device information and instructions in English; verify manufacturer and Australian sponsor identification and placement, legibility, warnings and applicable exceptions against the device and pack format.
Check UDI by device type, class, transition status and sponsor control. The phased mandatory rollout began on 1 July 2026 for Class IIb and III devices; later classes have other dates and exceptions. Class I non-sterile/non-measuring and Class Im measuring devices are outside mandatory UDI scope; Class Is, Class IIa and IVD classes have later staged dates. Check transition and specific exemptions for the units being supplied. Within Class 1 IVDs, TGA identifies instruments and software as within UDI scope, rather than treating every Class 1 IVD alike.
For products with radios, determine whether ACMA documentation, supplier registration and Regulatory Compliance Mark are required; TGA compliance does not dispense with them.
Public-facing therapeutic claims must be supported, accurate and consistent with the ARTG entry. Do not advertise the product as “TGA approved” or use the TGA logo as an endorsement.

Australian ARTG, label and software changes requiring reassessment

ARTG inclusion is the start of controlled supply, not the end of compliance. Maintain a change-impact register that asks:

Does a new indication, target population, clinical algorithm, firmware or accessory change the intended purpose or Australian risk class?
Does a new manufacturing site, sterilisation process, material, supplier or design affect conformity evidence, ARTG details or required TGA notification?
Does a label, package, UDI carrier, software version or marketing update create a mismatch with the evidence and ARTG entry?
Can the sponsor trace affected devices and obtain manufacturer investigation, adverse-event and corrective-action information promptly?

National medical-device scope versus wearable-specific assessment

This national page maps the interaction of Australian regimes for medical devices generally. For sensor-led, body-worn products, read the dedicated Australian wearable medical-device requirements route map, which focuses on continuous monitoring, body-contact, wireless and software-specific issues. Overseas medical-device pages describe their own jurisdictions and cannot replace Australian classification. Without a final intended-use statement, full specifications, evidence package and Australian supply model, nobody can responsibly promise a class, cost, exemption or launch date.

Questions specific to Australian medical devices

Does CE marking or FDA clearance allow immediate sale in Australia?

No. Appropriate evidence from comparable overseas bodies can support an Australian application where the device and indications match, but the relevant sponsor normally still needs ARTG inclusion before supply.

Can an ordinary Class I device be self-declared without any ARTG entry?

Some low-risk products use manufacturer declaration of conformity rather than third-party certification, but eligible Class I devices generally still require ARTG inclusion before ordinary supply unless a genuine exemption or exclusion applies.

Is a diagnostic app without a physical product regulated?

Potentially. Its intended diagnostic, monitoring, prediction or treatment role can make it a medical device; assess software-specific Australian rules and exclusions. Merely storing or transmitting patient records does not necessarily make software a device.

Does an ARTG inclusion by one Australian distributor cover another distributor?

Not automatically. ARTG entries are sponsor-specific. A different sponsor must verify its own lawful pathway even where the physical product is identical.

When must our product carry Australian UDI and an RCM?

UDI depends on class, IVD status, supply/transition facts and the applicable staged dates. RCM arises under relevant ACMA or electrical compliance rules, not simply because the device is medical; check both separately.

Selected official Australian sources

Legislation and classification: Law text; Classification guidance; IVD classification ; Amendment effective 8 September 2026
Boundary products: Boundary products
Essential Principles and manufacturer evidence: Essential Principles evidence; Manufacturer Evidence
Market inclusion and overseas evidence: ARTG inclusion process; Use of overseas evidence
Labelling and UDI: Device labelling; UDI timetable ; UDI scope and exclusions
Advertising and post-market: Advertising rules; Post-market duties
ACMA equipment rules and radiation regulators: ACMA equipment compliance; Radiation regulators ; Electrical safety scheme scope ; EESS medical-equipment scope guidance

Decision aid only. A final route requires the actual product specification and confirmation of current TGA requirements.